Progress in the clinical application of all-trans-retinoic acid in solid tumors
All-trans-retinoic acid(ATRA)is the clinical choice for the treatment of acute promyelocytic leukemia.However,in recent years,a large number of studies have shown that ATRA maintains the human normal immune microenvironment by inhibiting the immune escape effect of tumor stem cells and promoting the differentiation of myeloid-derived suppressor cells,and enhances the efficacy of chemotherapeutic drugs,targeted drugs and immunotherapy drugs in solid tumors.This paper reviewed the clinical trial progress of ATRA in solid tumors to provide a reference for its further clinical application.